Diabetes drug shows promise against advanced prostate cancer in new trial
Disease control
Not yet recruiting
This phase 2 trial tests whether adding dapagliflozin, a common diabetes medication, to standard hormone therapy can better control metastatic castrate-resistant prostate cancer. About 60 adults with advanced prostate cancer that has stopped responding to hormone therapy will be …
Phase: PHASE2 • Sponsor: Yung NA • Aim: Disease control
Last updated May 13, 2026 16:03 UTC